RETRACTED ARTICLE: Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment

Ahmad, Niyaz; Am, Al-Subaiec; Sharma, Sonali; Alam, Morshed; Ashafaq, Mohammad; R, Abdur Rub; Ahmad, Faizan

doi:10.1080/21691401.2018.1561458

Cited by 30 publications

(24 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IR spectra of pure catechin hydrate (CH), PVA, PLGA-NPs, CH-loaded-PLGA-NPs, chitosan, and chitosan-coated-CH-loaded-PLGA-NPs were examined through an attenuated total reflectance (ATR, wavenumber 4000-400 cm −1 ). All the samples were analysed in their original forms without any kind of preparation [46].…”

Section: Fourier Transform Infrared Spectroscopy (Ftir)-based Attenuamentioning

confidence: 99%

“…At every time point, we withdrew the test samples (1.0 mL). All samples were withdrawn and filtered by syringe filter (0.2 µm), after which the CH quantity was analysed through the in-house developed and validated UHPLC-MS/MS method reported in this manuscript [28,46].…”

Section: In Vitro Drug Releasementioning

confidence: 99%

“…The samples were filtered via a membrane filter for the analysis. The quantity of permeated CH was analysed through the in-house developed and validated UHPLC-MS/MS method reported in this manuscript [46].…”

Section: Nasal Mucosa Based Ex Vivo Permeation Studiesmentioning

confidence: 99%

“…The blood of four rats from each group was collected, and then the rats were scarified, followed by immediate removal of the brains and lungs. The homogenate was prepared for all samples separately and analyzed by the in-house bioanalytical method [46].…”

Section: Pharmacokinetic (Pk) Studymentioning

confidence: 99%

See 3 more Smart Citations

Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy

et al. 2020

Self Cite

View full text Add to dashboard Cite

To formulate novel chitosan (CS)-coated–PLGA–nanoparticles (NPs) using a central composite design approach and use them in order to improve brain bioavailability for catechin hydrate (CH) through direct nose-to-central nervous system (CNS) delivery for the evaluation of a comparative biodistribution study of CH by the newly developed ultra high performance liquid chromatography mass spectroscopy and mass spectroscopy (UHPLC-MS/MS) method in the treatment of epilepsy. For PLGA–NPs’ preparation, a double emulsion-solvent evaporation method was used, where a four-factor, three-level central composite design was used to obtain the best nanoformulation. For the optimization, four independent variables were chosen, that is, PLGA, polyvinyl alcohol (PVA), sonication time, and temperature. The optimized PLGA–NPs were further coated with chitosan and assessed for drug release, nasal permeation study, as well as a comparative pharmacokinetic and pharmacodynamic study. Independent and dependent variables helped to optimize the best nanoformulation based on the composition of PLGA (50.0 mg), PVA (1.10%), sonication time (90.0 s), and temperature (25.0 °C). The values of dependent variables were observed, such as polydispersity index (PDI), particle size, and zeta potential (ZP)—that is, 0.106 ± 0.01, 93.46 ± 3.94 nm, and −12.63 ± 0.08 mV, respectively. The ZPs of CS-coated PLGA–NPs were changed from negative to positive value with some alteration in the distribution of particle size. Excellent mucoadhesive-nature of CS–CH–PLGA–NPs as compared with CH–S and CH–PLGA–NPs was seen, with a retention time of 0.856 min and m/z of 289.23/245.20 for CH, together with a retention time of 1.04 min and m/z of 301.21/151.21 for Quercetin as an internal standard (IS). For a linear range (1–1000 ng mL−1), % accuracy (93.07–99.41%) and inter- and intraday % precision (0.39–4.90%) were determined. The improved Cmax with area under curve (AUC)0–24 was found to be highly significant (p < 0.001) in Wistar rats’ brain as compared with the i.n. and i.v. treated group based on the pharmacokinetics (PK) results. Furthermore, CS–CH–PLGA–NPs were found to be more significant (p < 0.001) for the treatment of seizure threshold rodent models, that is, increasing current electroshock and pentylenetetrazole-induced seizures. A significant role of CS–CH–PLGA–NPs was observed, that is, p < 0.001, for the enhancement of brain bioavailability and the treatment of epilepsy.

show abstract

Section: Fourier Transform Infrared Spectroscopy (Ftir)-based Attenuamentioning

confidence: 99%

Section: In Vitro Drug Releasementioning

confidence: 99%

Section: Nasal Mucosa Based Ex Vivo Permeation Studiesmentioning

confidence: 99%

Section: Pharmacokinetic (Pk) Studymentioning

confidence: 99%

See 2 more Smart Citations

Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…85 Another distinct strategy that was not shown with liposomes is to coat micelles with chitosan or conjugate wheat germ agglutinin to their surfaces to enhance interaction with the nasal mucosa when delivered by IN injection. 86,87 A unique development in the relationship between polymer-and lipid-based carriers is the use of lipid layers as coating for polymeric micelles to extend the half-life of micelles and improve their biocompatibility. PLGA nanoparticles had been loaded with panax notoginsenoside (PNS) and coated with a liposomal layer before being administered via the IG route by gavage.…”

Section: Polymer-based Carriers Micellesmentioning

confidence: 99%

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Alkaff¹,

Radhakrishnan²,

Nedumaran³

et al. 2020

IJN

View full text Add to dashboard Cite

The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid-and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbonbased DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.

show abstract

Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase‐1 associated with cardiovascular diseases

Demir

2020

Drug Development Research

View full text Add to dashboard Cite

Paraoxonase‐1 (PON1) has essential roles such as protecting low‐density lipoprotein against detoxification and oxidation of highly toxic compounds. Quinones are a class of compounds and a type of plant‐derived secondary metabolites. Here, PON1 was purified using very simple methods and evaluation of the interactions between the enzyme and some quinones. It was found that these quinones displayed effective inhibitor properties for PON1 with the IC50 values in the range of 3.27–82.90 μM and the K i values in the range of 2.50 ± 0.65 to 30.90 ± 7.20 μM. These quinones displayed distinct inhibition mechanisms. It was determined that except for 5‐hydroxy‐2‐methyl‐1,4‐naphthoquinone and 2‐methyl‐1,4‐naphthoquinone all quinones exhibit competitive inhibition effects. Also, molecular docking and in silico ADME studies were performed. Usage of drugs including quinone derivatives in structure with biological activity would be hazardous in some cases.

show abstract

RETRACTED ARTICLE: Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment

Abstract: Rub & Farhan Jalees Ahmad (2019) Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment,

Cited by 30 publications

References 71 publications

Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy

Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase‐1 associated with cardiovascular diseases

Contact Info

Product

Resources

About